<DOC>
	<DOC>NCT01508923</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes mellitus Diet treated and/or subjects in monotherapy with max. 50 % of maximal dose of sulphonylurea (SU). In addition, subjects in treatment with metformin and/or repaglinide could be included Body Mass Index (BMI) maximum 35 kg/m^2 Fasting plasma glucose 715 mmol/l, both inclusive Impaired liver function Impaired renal function Anaemia Cardiac disease Uncontrolled treated/untreated hypertension Recurrent major hypoglycaemia as judged by the Investigator Known or suspected allergy to trial product or related products Females of child bearing potential who are pregnant, breastfeeding or have intention of becoming pregnant or are not using adequate contraceptive measures Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness Loss of more than 400 ml blood during the three months prior to study start Allergy to paracetamol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>